Welcome to our dedicated page for Akebia Therapeutics SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Akebia Therapeutics, Inc. filings document the regulatory record of a commercial-stage biopharmaceutical company focused on kidney disease therapeutics. Its 8-K reports include quarterly and annual operating results, Vafseo® commercialization updates, pipeline disclosures, Regulation FD presentations, and material agreements tied to licensing, supply, and corporate facilities.
Akebia’s proxy materials describe board composition, committee assignments, director elections, executive compensation, equity plans, and shareholder voting matters. The filing record also covers governance changes, Nasdaq-listed common stock matters, risk and business disclosures related to commercial products, clinical programs, collaborations, lease obligations, and capital-structure activity.
Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported multiple automatic stock sales tied to equity compensation. On February 2, 2026, she sold 16,846, 25,382, and 27,544 shares of Akebia common stock at $1.39 per share in separate transactions.
The filing states one sale was made under a Rule 10b5-1 trading plan adopted on September 8, 2025. The other sales were made automatically by Akebia to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on January 31, 2023, January 31, 2024, and January 31, 2025. After these transactions, Rucci directly beneficially owned 588,378 shares of common stock.
Akebia Therapeutics, Inc. executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer, reported a sale of common stock. On February 2, 2026, he sold 34,951 shares at $1.39 per share.
According to the filing, the sale was made automatically by Akebia to cover tax withholding obligations tied to the vesting and settlement of one-third of his restricted stock units granted on January 31, 2025. The transaction was carried out under a Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owns 672,635 shares of Akebia common stock directly.
Akebia Therapeutics CEO and President John P. Butler, who is also a director, reported several transactions in Akebia common stock on February 2, 2026. He sold 46,660, 96,065, 114,891, and 83,689 shares at $1.39 per share. According to the footnotes, most of these sales were made automatically by the company to cover tax withholding when restricted stock units and performance stock units vested, and were executed under a Rule 10b5-1 trading plan adopted on September 8, 2025. Butler also acquired 175,250 shares at $1.41 per share upon vesting of performance-based restricted stock units after a stock price performance condition was certified and met. Following these transactions, he directly held 3,297,794 shares and indirectly held 159,928 shares through the Dorothy Butler Revocable Trust dated November 20, 2007.
Akebia Therapeutics’ Chief Commercial Officer Nicholas Grund received new equity awards, aligning his compensation with company performance. On January 30, 2026, he was granted 204,000 shares of common stock as restricted stock units at $0.00 per share, bringing his directly owned common stock to 646,579 shares.
He was also granted a stock option for 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. The RSUs vest in three equal annual installments, while the options vest over four years, both subject to his continued service.
Akebia Therapeutics disclosed that SVP and Chief Medical Officer Steven K. Burke received new equity awards on January 30, 2026. He was granted 204,000 restricted stock units of common stock at no cost and 320,000 stock options with a $1.41 exercise price.
The 204,000 restricted stock units vest in three equal installments on the first, second, and third anniversaries of the grant date, conditioned on continued service. The 320,000 options vest over four years, with 25% after one year and the remaining 75% in equal quarterly installments. Following the grant, Burke directly beneficially owns 1,016,090 shares of common stock, including 3,000 shares acquired through the company’s employee stock purchase plan.
Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported new equity awards. On January 30, 2026, she received 190,000 shares of common stock in the form of restricted stock units at $0.00 per share, bringing her directly held common stock to 658,150 shares.
She was also granted a stock option for 270,000 shares of common stock with a $1.41 exercise price, all held directly. The restricted stock units vest in three equal annual installments, while the options vest over four years, both subject to continued service with the company.
Akebia Therapeutics reported an equity grant to SVP and Chief Accounting Officer Richard C. Malabre. On January 30, 2026, he received 79,000 restricted stock units and 119,000 stock options with a $1.41 exercise price, issued under Akebia’s 2023 Stock Incentive Plan.
The restricted stock units vest in three equal annual installments on the first, second and third anniversaries of the grant date, assuming continued service. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal quarterly installments. After this grant, Malabre beneficially owns 348,914 shares of common stock, including shares bought through the company’s employee stock purchase plan, and holds 119,000 stock options.
Akebia Therapeutics reported an equity compensation grant to its senior executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer. On January 30, 2026, he received 204,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 707,586 shares.
He was also granted stock options covering 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. One third of the restricted stock units vest on each of the first three anniversaries of the grant date, while 25% of the options vest on the first anniversary and the remaining 75% vest in equal quarterly installments over the following three years, in each case contingent on continued service.
Akebia Therapeutics CEO and President John P. Butler reported new equity awards on January 30, 2026. He received 743,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 3,463,849 shares.
He was also granted a stock option for 1,115,000 shares at an exercise price of $1.41 per share, expiring on 01/30/2036. These options vest over four years, while the restricted stock units vest in three equal annual installments, both subject to his continued service. An additional 159,928 shares are held indirectly through the Dorothy Butler Revocable Trust.
Akebia Therapeutics executive Carolyn M. Rucci, SVP and Chief Legal Officer, filed an initial ownership report showing her equity position in the company. She reports beneficial ownership of multiple blocks of Akebia common stock, including 171,816 shares held directly and additional shares linked to restricted stock unit grants.
The filing also lists several employee stock options to buy Akebia common stock, with exercise prices ranging from $0.63 to $2.88 per share and expiration dates between 2031 and 2035. These options generally vest over four years, with 25% vesting after one year and the remainder in equal quarterly installments, subject to continued service.